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Abstract: The review intends to present and recapitulate the current knowledge on the roles and im-
portance of regulatory RNAs, such as microRNAs and small interfering RNAs, RNA binding proteins 
and enzymes processing RNAs or activated by RNAs, in cells infected by RNA viruses. The review 
focuses on how non-coding RNAs are involved in RNA virus replication, pathogenesis and host  
response, especially in retroviruses HIV, with examples of the mechanisms of action, transcriptional 
regulation, and promotion of increased stability of their targets or their degradation.
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1. INTRODUCTION 
 RNA agents have been shown to play essential roles in 
evolution and regulation in all D N A /protein based life: 
based on RNA stem-loop secondary structures (built of 
paired stems and not-paired loops), pseudoknots, and loops 
with sequences showing affinity to target proteins. Group I 
and group II introns, viroids, viral (RN A  and DNA viruses, 
bacteriophages, retrotransposons, Long Terminal Repeats) 
networks cooperate within cellular genomes as modular. 
Some non-coding RNAs have built complementary consor-
tia, such as rRNAs, tRNAs, spliceosomes, editosomes, and 
other ribonucleoprotein particles (RNPs) [1]. Additionally, 
counterbalancing modules such as restriction/modification 
(RM) modules have evolved, assuring identity (self/non-self) 
of organisms. All fine-tuned steps of key cellular processes 
such as gene expression, transcription, translation, D N A  
recombination and repair, epigenetic imprinting, as well as 
various forms of innate and adaptive immunity, are essen-
tially constituted by natural genetic content operators. 
 There are many reports showing that virus infection can 
alter the cellular microRNAs (miRNAs) to affect virus repli-
cation, some of them oppose the function of host restriction 
factors to enhance virus proliferation [2, 3]. Nowadays, re-
searchers are trying to design miRNAs against virus proteins 
to control virus replication. 
 In the organisms, RNAs are associated to RNA binding 
proteins, helicases and RNases involved in RNA degradation 
and turnover.  
 This review discusses how these RNA interacting pro-
teins and networks of regulatory RNAs are integrated into 
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the general network of pathogenesis’ control, especially dur-
ing RNA virus infection. 
1.1. RNA Viruses 
 Human diseases causing RNA viruses include Ortho-
myxoviruses, Hepatitis C Virus (HCV), Ebola disease, 
SARS, influenza, polio measles and retrovirus including 
adult Human T-cell lymphotropic virus type 1 (HTLV-1) and 
human immunodeficiency virus (HIV). RNA viruses have 
RNA as genetic material, that may be a single-stranded RNA 
or a double stranded RNA. Viruses may exploit the presence 
of RNA-dependent RNA polymerases for replication of their 
genomes or, in retroviruses, with two copies of single strand 
RNA genomes, reverse transcriptase produces viral DNA 
which can be integrated into the host DNA under its inte-
grase function. Studies showed that endogenous retroviruses 
are long-terminal repeat (LTR)-type retroelements that ac-
count for approximately 10% of human or murine genomic 
DNA.  
 Among human retroviruses, HIV-1 is a lentivirus with an 
RNA genome formed by two copies of a single-stranded, 
positive-sense RNA. The HIV-1 RNA genome is associated 
to the nucleocapsid protein (NC) and to viral enzymes, thus 
it is “protected” within the viral capsid mainly formed by the 
p24 protein. Upon entry into the target cell, the viral RNA 
genome is reverse transcribed into double-stranded DNA by 
a virally encoded reverse transcriptase that is transported 
along with the viral genome into the virus particle. The viral 
DNA is imported into the cell nucleus and integrated into the 
cellular DNA by a virally encoded integrase and host co-
factors. Once integrated, the virus may become latent, or 
may be transcribed, producing new RNA genomes and viral 
proteins that are packaged and released from the infected cell 
as new virus particles that will infect other cells to begin the 
new replication cycle. Many aspects of the life cycle of ret-
roviruses are intimately linked to the functions of cellular 
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proteins and RNAs. HIV-1 and Moloney Murine Leukemia 
Virus (MoMuLV) have been studied for the dimerization of 
two RNAs. 
1.2. Retrotransposons, LTRs, Retrotranscriptases 
 Long Interspersed Nuclear Elements-1 (LINE-1) and en-
dogenous retroviruses (HERVs) encode reverse transcriptase 
(RT) proteins in vertebrates. LINE-1s (L1s), the most studied, 
active autonomous mobile DNA in humans, accounts for 
about 17% of human DNA while HERVs account for about 
8% and, together with the non-autonomous SINE/Alu family 
(about 10%) constitute a large proportion of the human ge-
nome. L1s encode two open reading frames (ORFs 1 and 2). 
The shorter ORF1 translation product (ORF1p) is an RNA 
binding protein, thought to also bind to non-retroviral tran-
scripts, protects against nuclease degradation and specify nu-
clear import of the ribonuclear protein complex (RNP). ORF2 
encodes a multifunctional protein (ORF2p) comprising 
apurinic/apyrimidinic endonuclease (APE) and reverse-
transcriptase (RT) activities, responsible for retroelement’s 
replication and their integration into chromosomal DNA. 
However, some clades of APE-type retroelements only encode 
a single ORF-corresponding to the multifunctional ORF2p [4]. 
HERVs, closely resembling infectious retroviruses, have mu-
tated and/or truncated provirus structures and have lost their 
ability to replicate or retrotranspose. Nonetheless, proteins 
encoded by different types of HERVs are still exerting bio-
logical activities and most of the HERV-associated regulatory 
regions, termed “long terminal repeats” (LTRs), preserve their 
functions as a promoter–enhancer region. Functional “awak-
ening” of HERVs and LTRs from their epigenetic silencing 
can play causative roles in tumorigenesis; in particular, 
HERV-K (HML-2), the most recently integrated family with a 
nearly complete retroviral structure, is involved in neoplastic 
and autoimmune pathological processes [5]. Retroelements, 
which mobilize throughout the genomes by a copy-and-paste 
process involving RNA intermediates, have the potential to 
modify mammalian genomes not only through insertional 
mutagenesis yet generating many other novelties that alter 
genomes both structurally and functionally [6]. Not surpris-
ingly, cells have adopted strategies aiming at restricting the 
mobility and deleterious consequences of uncontrolled retro-
transposition [6]. 
 Although heavily mutagenic and responsible for deleteri-
ous gene disruptions, retroelements may have provided some 
beneficial genomic functions with potential evolutionary 
advantages.  
 Incubation of mouse zygotes with 5-bromodeoxyuridine 
(BrdU) yields massive incorporation of this nucleoside ana-
logue in newly synthesized DNA; surprisingly, a significant 
incorporation still occurs in both zygotic pronuclei in the 
presence of aphidicolin, a specific inhibitor of DNA replica-
tion. This aphidicolin-resistant BrdU incorporation is quanti-
tatively abolished when embryos are simultaneously exposed 
to abacavir, a nucleoside RT inhibitor, thus revealing its RT-
dependent nature. Moreover, quantitative PCR analysis 
showed that LINE-1 copies are newly synthesized at the zy-
gote- and two-cell embryo stages and nearly doubled com-
pared to gamete copy number. These findings support the 
conclusion that RT-dependent amplification of LINE-1 retro-
transposons is a distinctive feature of early embryonic ge-
nomes [7]. 
 Inhibition of RT activity in cancer cell lines, either by 
LINE-1-specific RNA interference or by RT inhibitory 
drugs, was found to reduce proliferation and promote differ-
entiation and to antagonize tumor growth in animal models. 
Using CsCl density gradients, Alu- and LINE-1-containing 
DNA:RNA hybrid structures were identified in cancer yet 
not in normal cell lines [8]. In cancer cells the highly abun-
dant RT activity intercepts various RNA classes and reverse 
transcribes them generating RNA:DNA hybrids. This may 
impair the formation of double-stranded RNAs required in 
the production of small regulatory RNAs (miRNA in particu-
lar), with a direct impact on gene expression. RT inhibition 
restores the 'normal' small RNA profile and the regulatory 
networks that depend on them. Thus, the retrotransposon-
encoded RT drives a previously unrecognized mechanism 
crucial to the transformed state in tumor cells. 
 Recent computational studies confirm the association 
between L1 expression and the generation of small RNAs. 
L1 expression seems to have a role in the activation of small 
RNA expression as emerged comparing data from L1-active 
and L1-silenced breast cancer cells. Cells in which L1 ex-
pression was silenced greatly increased the expression of a 
number of miRNAs, in particular members of the let-7 fam-
ily, few piwiRNAs and several repeat-RNAs targeting LTRs, 
LINEs and SINE elements [9].
1.3. Small RNAs, miRNAs, RNA Interference and Im-
munity 
 miRNAs have become a prototype of several classes of 
small RNAs (sRNAs) [10]. These sRNAs act as single strand 
filaments incorporated into the RNA induced silencing com-
plexes (RISC) acting as guides to Argonaute (Ago) enzymes 
degrading the target RNA complementary to these sRNAs. 
The processing into mature sRNAs requires protein com-
plexes containing endoribonucleases: DROSHA in the nu-
cleus, cleaving the dsRNA precursors into pre-miRNAs. The 
pre-miRNA hairpin structure is then exported into the cyto-
plasm via exportin-5. In the cytoplasm it assembles in RNA 
induced silencing complex (RISC) which includes Dicer 
ribonucleases that cleave pre-miRNAs into mature single 
strand sRNAs, Ago enzymes cleaving the mRNAs with se-
quences complementary to the microRNAs [11], and other 
associated proteins, such as PW182/Argonaute-2, a 182 kDa 
RNAse associated to P-bodies [12], HIV transactivating re-
sponse RNA-binding protein (TRBP) [13], and fragile X 
mental retardation protein (FMRP1) [14]. Mature miRNAs 
play important roles in the regulation of mammalian genes. It 
has been suggested that over 30% of all human genes are 
regulated by miRNAs. While recent genome-wide siRNA 
and shRNA screenings have shown that several hundred host 
cell proteins contribute to the regulation of HIV-1 infection 
in human cells, how miRNA-mediated regulation comple-
ments this picture is poorly understood. Other processing 
complexes are involved in the production of sRNA with 
various sizes: piwiRNA and siRNA, with size ranging from 
21-nt to 25-nt, is the output of this processes. Their role is in 
the amplification of signals such as RNA primed RNA am-
plification, and the spreading of anti-viral RNA interference 
mechanism.  
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1.4. RNA Pseudoknots, Hairpins and Secondary Struc-
tures 
 RNA can both store information in its linear sequence 
and take on critical structural and catalytic roles in the cell, 
such as during the translation of messenger RNA into pro-
teins [15]. These latter functions depend on the complex 
higher-order structures RNA is able to form. Homan et al.
reported a method to probe the intricate conformational 
states in the analysis of HIV-1 NL4-3 RNA genome [15]. 
They chemically modified exposed segments of three com-
plex RNA structures. They then sequenced the RNA to map 
the locations of the multiple modifications in each individual 
linear RNA molecule. This allowed the researchers to deduce 
interactions in three-dimensional space, and to uncover the 
local conformation, providing valuable information on the 
folding and function of RNAs [15]. Single-molecule RNA 
structure was tagged, i.e. multiple sites were chemically 
modified are identified by massively parallel sequencing of 
single RNA strands, and then analyzed for correlated and 
clustered interactions. The strategy thus identified RNA in-
teraction groups by mutational profiling (RING-MaP) and 
made possible two applications. Firstly, through space inter-
actions, 3D models were created for RNAs, spanning 80–265 
nucleotides, and intramolecular interactions that stabilize 
RNA were characterized. Secondly, distinct conformations 
in solution were identified and revealed previously unde-
tected hidden states and large-scale structural reconfigura-
tions that occur in unfolded RNAs relative to native states. 
RING-MaP analysis of single-molecule nucleic acid struc-
ture enabled a novel view of the global architecture and mul-
tiple conformations that govern the functions in RNAs. 
 Additional methodologies that have been used in testing 
the secondary structure of RNA genomes have been pub-
lished. 2’-hydroxy acylation of RNA was analysed by primer 
extension and mutational profiling (SHAPE-MaP) [16] and 
used to define a new model of HIV-1 RNA genome.  
 Advances in RNA structure prediction from sequence are 
currently made by setting and testing new tools for generat-
ing hypotheses and confirming viral RNA structure-function 
relationships [17]. On this basis, novel methods have been 
tested to investigate the sequence-dependence of RNA-
protein interactions [18]. RNA substrates demonstrate di-
verse intramolecular interactions, including mismatched base 
bulges, stem loops, pseudoknots, g-quartets, divalent cation 
interactions and noncanonical base pairs, determining three-
dimensional RNA structure. The molecular evolution of 
MS2 from low- to high-affinity hairpins, was analysed and 
quantified. The results suggest that quantitative analysis of 
RNA on a massively parallel array (RNA-MaP) provided an 
insight into the biophysics of RNAs and on consequences of 
sequence-function relationships. 
 Several RNA secondary structures have been shown im-
portant for the virus functions: internal ribosomal entry 
structure, internal ribosomal entry site, and 5' UTRs regulate 
the start of translation of operons. For example, in influenza 
virus type C, there are seven vRNA segments with non-
coding regions (NCR) at the extremities, that affects tran-
scription and replication, by the type-C and type-A polym-
erase complexes [19]. To determine the molecular structure 
adopted by these NCR, various bioinformatics tools, includ-
ing RNAfold, RNAstructure, Sfold, and Mfold, have been 
used. Various nucleotide polymorphisms (SNPs) in these 
non-coding regions may differentiate infective strains, such 
as major or minor read-through activity and differential ex-
pression of ORFs in operons. In Orthomyxoviridae, such as 
human influenza viruses or infective salmon anemia virus 
(ISAV), studies suggest an association between the molecu-
lar architecture of NCR regions and their role in the viral life 
cycle [20]. The 3' and 5'-terminal sequences of influenza A, 
B and C virus RNA segments are highly conserved and show 
partial inverted complementarity [21]. The viral RNA 3’- 
and 5’-end structure and mRNA transcription of infectious 
salmon anaemia virus resemble those of influenza viruses 
[22]. The aligned Non-Coding Region (NCR) sequences 
from ISAV isolates were compared with those from influ-
enza virus, and consensus sequences were found, based on 
conserved regions identified in the consensus sequence [23]. 
This hypothetical structure, together with a comparison with 
influenza viruses, yielded reliable secondary structure mod-
els that lead to identification of conserved nucleotide posi-
tions at inter-genus level to determine which nucleotide posi-
tions are involved in the recognition of the vRNA/cRNA by 
RNA-dependent RNA polymerase (RdRp) or mRNA by the 
ribosome. The NCR contain conserved sequences that vary 
in length among the various genera of the family Ortho-
myxoviridae [24]. It has been reported that the first 12 and 
13 nucleotides correspond to conserved sequences in the 3’ 
and 5’ ends, respectively, of all segments of the influenza A 
vRNA [25]. Structurally, these conserved sequences in influ-
enza A have been described as partially complementary and 
capable of interacting in cis within each segment of RNA, 
forming structures called panhandles [26, 27] In Ortho-
myxoviruses, transcription of the genome requires the vRNA 
to act as template for each genomic segment, and for tran-
scription to occur, the conformation adopted via the folding 
of the NCR is essential [26].  
1.5. HIV-1: Host Factors Supporting From the Entry to 
Virus Replication 
 Recently importin 7 and importin  have been shown to 
enhance nuclear entry of HIV-1 (but not HIV-2) correlating 
with its ability to bind to the viral integrase and the virus 
accessory protein Vpr which are components of pre-
integration complex (PIC) [28, 29]. Transportin 2, identified 
using siRNA screens [30-32], is also able to enhance nuclear 
import of PIC. The most important finding was that tRNA 
molecules themselves can act as nuclear entry chaperones for 
the HIV PIC. HIV-1 transcription is regulated by the viral 
promoter located in the 5LTR of the provirus. The LTR con-
tains binding sites for several transcription factors such as 
Sp1 and NF-B, NFAT, LEF-1, COUP-TF, Ets1, USF and 
AP-1 [33].  
 The RNA binding protein Staufen appears to act as a 
chaperone to the RNA and has been detected in viral parti-
cles. Similarities between this and the known HIV TAR 
RNA binding protein TRBP may promote further investiga-
tions. 
 RNA cap methylases are cellular factors that regulate 
post transcriptional HIV-1 RNA expression in order to pro-
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duce a viral mRNA camouflaged by cellular mRNA showing 
a 7-methylguanosine (m7G) cap. 
1.6. RNA Silencing and Host-virus Interaction 
 Plants and lower eukaryotes produce miRNAs and siR-
NAs as a form of RNA-interference (RNAi) to restrict in-
fecting viruses. While mammals conserve the same func-
tional miRNA repertoire and RNA-silencing machinery, 
some have debated whether they employ a miRNA-based 
antiviral strategy. For endogenous mammalian retroviruses, 
there is a large body of literature demonstrating that a variety 
of small non-coding RNA forms are employed to silence 
these elements. In silico analyses have also indicated that 
exogenous mammalian viruses may be similarly susceptible 
to miRNA-based restriction. The notion that miRNAs restrict 
viruses in mammals as they do in invertebrate or plant cells 
is supported by increasing examples of RNAi-silencing sup-
pressors encoded by mammalian viruses such as Adenovirus, 
HCV, Ebola, Influenza A virus, primate foamy virus, HIV, 
SARS corona virus and HTLV-1. Further investigation is 
needed to understand how RNA-based and protein-based 
viral restriction mechanisms cooperate together in human 
cells. 
 Considering tumour- associated viruses (oncoviruses), it 
is estimated that 20% of all cancers are linked to infectious 
agents. Studies of oncogenic DNA viruses have contributed 
to the understanding of key molecular mechanisms of tu-
morigenesis and viral oncogenicity [10]. Virally encoded 
oncoproteins such as adenovirus E1A and human papillo-
mavirus (HPV) E7 can bind an array of cellular proteins to 
override proliferation arrest. Adenovirus VA1 noncoding 
RNA can inhibit small interfering RNA and microRNA bio-
genesis, both by inhibiting nuclear export of shRNA or pre-
miRNA precursors, competing for the Exportin 5 nuclear 
export factor, and inhibiting Dicer function by direct binding 
to Dicer [10]. Recently, many viral-encoded miRNAs have 
been discovered, especially abundant in viruses transcribed 
from double-stranded DNA genomes. Several virus-encoded 
miRNAs have unique aspects to their biogenesis, such as the 
location within the precursor transcript.  
 Bovine leukemia virus, a member of the retrovirus fam-
ily, was the first RNA virus shown to synthesize a viral RNA 
that is proficiently processed in cells into small ncRNAs 
[34], producing numerous miRNAs. BLV avoids Drosha-
mediated cleavage of its genome and mRNAs, which overlap 
the miRNA cluster, since BLV miRNAs, unlike most known 
miRNAs, are encoded as shorter RNA polymerase III (pol 
III) transcribed hairpins that can directly serve as Dicer sub-
strates. Thus, BLV transcripts are not cleaved by Drosha, 
while subgenomic small RNAs are processed into miRNAs. 
 Influenza A virus replicates its genome in the nucleus 
and is exposed to the nuclear microRNA processing factors 
Drosha and DGCR8. At 8 hours after infection, 18- to 27-nt 
small viral leader RNAs (leRNAs) bearing a 5'-terminal 
triphosphate are produced from the 5' ends of all eight influ-
enza virus genomic RNA (vRNA) segments [35]. The high-
level production of leRNAs may imply a role in the regula-
tion of the switch from viral mRNA transcription to genomic 
RNA synthesis. 
 It is generally believed that cytoplasmic RNA viruses do 
not encode miRNAs, owing to inaccessible cellular miRNA 
processing machinery. In a genome-wide analysis and identi-
fication of miRNAs originating from hepatitis A virus (HAV), 
a typical cytoplasmic RNA virus [36], two novel virally en-
coded miRNAs, hav-miR-1-5p and hav-miR-2-5p, were iden-
tified, generated from viral miRNA precursors (pre-miRNA).  
 Presently, functions have been proposed for viral miR-
NAs from three different viral families: herpesviruses, 
polyomaviruses and retroviruses.  
 Four vsRNAs were detected in enterovirus 71-infected 
cells using next-generation sequencing and northern blots. 
Viral infection produced substantial levels (>105 copy num-
bers per cell) of vsRNA1, one of the four vsRNAs. Dicer 
was shown to be involved in vsRNA1 generation in infected 
cells. vsRNA1 overexpression inhibited viral translation and 
IRES activity in infected cells. Conversely, blocking 
vsRNA1 enhanced viral yield and viral protein synthesis. 
vsRNA1 targets stem-loop II of the viral 5' untranslated re-
gion and inhibits the activity of the IRES through this se-
quence-specific targeting [37]. 
 Websites and databases are available that classify most of 
the small RNAs and mRNAs produced by virus families 
[38]; In VIRMir database four miRNAs are recorded derived 
from HIV genome hiv1-miR-tar-5p, hiv1-miR-tar-3p, hiv1-
miR-n367, originating from nef gene and targeting nef 
mRNA [39], hiv1-miR-h1 [40]. In addition to these four, 
another one, hiv1-miRH3, was reported more recently [41], 
which locates in the mRNA region encoding the active cen-
tre of reverse transcriptase (RT), targets HIV 5’-LTR and 
binds to the TATA box, upregulating promoter activity [41].  
 The HIV-1 Trans-Activation Response (TAR) element is 
a hairpin structure of ~50 nucleotides found at the 5' end of 
the HIV viral mRNA. TAR element is recognized by the 
RNAi machinery and it has been shown to be processed by 
Dicer yielding a viral miRNA involved in chromatin remod-
elling of the viral LTR [42] and targeting the apoptosis genes 
ERCC1 and IER3 [43, 44]. This viral miRNA is detectable 
in infected cells and appears to contribute to viral latency.  
 In a recent publication [45] numerous small RNAs were 
found deriving from HIV-1 RNA genome. Most of the se-
quences, with positive polarity (98.1%) could be structured 
RNAs (sRNAs) or miRNA-like (vmiRNAs). A small portion 
of the viRNAs, with negative polarity, is encoded within the 
3-UTR. These viral siRNAs (vsiRNAs) were shown to act 
inhibiting virus replication, since their inhibition using an-
tagomiRs increases virus replication. Three of the HIV-1 
small RNAs were shown to be processed by the RNAi ma-
chinery. There are data showing that HIV-1 can express an 
antisense transcript from the 3'-end of its genome that forms 
long RNA duplexes with counterpart sense HIV-1 RNAs 
[46-48]. Most HIV sRNAs are not supposed to function as 
miRNAs, because of lack of evolutionary conservation 
amongst strains, but may still assume a hairpin structure in 
the regions containing the conserved bases.  
1.6.1. Host miRNAs Deregulated by Virus Infection 
 Presently, viral interactions with cellular miRNAs have 
been identified, expanding the knowledge of miRNA func-
tions [49]. 
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 One of the first host miRNAs shown to block retrovirus 
was miR-32, effectively limiting primate foamy virus type 1 
(PFV-1) replication [50].  
 Inhibition of influenza virus replication has been de-
scribed for four miRNAs: miR-323, miR-491, miR-654, and 
let-7c. Vesicular stomatitis virus is inhibited by miR-24 and 
miR-93, hepatitis B virus by miR-125a-5p, miR-199a-3p and 
miR-210; and HCV by miR-196, miR-296, miR-351, miR-
431, and miR-448 [51]. In the case of HCV, a liver-specific 
miRNA, miR-122, was found to directly target HCV RNA 
sequence to up-regulate viral replication [52].  
 Substantial advances have been made in the understand-
ing of the interplay between HIV-1 and the cell's RNAi ac-
tivity. HIV-1 infection can change the miRNA expression 
profiles in the circulating blood cells from infected individu-
als [51].  
 Host miRNAs can modulate HIV replication either di-
rectly by targeting HIV RNA, or targeting the mRNAs that 
encode host cell factors relevant to HIV replication. miR-217 
was found induced by Tat and increased HIV-1 expression 
by targeting sirtuin-1 (SIRT-1) with deacetylase activity in-
activating Tat function [53]. miR-198 was shown to inhibit 
HIV-1 gene expression and replication in monocytes, action 
linked to its down-regulation of cyclin T1 [54].  
 Recent reports studied several human miRNAs targeting 
HIV-1 sequences. Using target prediction software, five 
miRNA (miR-29a, miR-29b, miR-149, miR-324-5p, and 
miR-378) were found to target sequences, two of them lo-
cated in the viral nef gene, of the HIV-1 genome [55]. miR-
29a was shown to inhibit nef expression, and to repress HIV 
replication in Jurkat cells. Recently inhibition of HIV-1 in-
fection by miR-29a and miR-29b was confirmed [56, 57], 
however, HIV-1 is protected by a complex RNA secondary 
structure surrounding the target site. A different group of 
five miRNAs (miR-28, miR-125b, miR-150, miR-223, and 
miR-382) that target the 3'-UTR of the HIV genome was 
reported [58]. These “anti-HIV” miRNAs were shown to be 
enriched in resting CD4+ T cells and were hypothesized to 
be involved in proviral latency. In another study, four of 
these miRNAs were found responsible for differences be-
tween monocytes and macrophages in their permissivity to 
HIV infection [59]. Recently the action of miR-29, miR-
133b, miR-138, miR-149 and miR-326, targeting HIV-1 se-
quences, was shown [60]. Therefore, in divergent cells and 
in varying contexts different miRNAs may selectively regu-
late HIV-1 infection through direct targeting viral sequences. 
Thus, a complex set of miRNA-mediated positive and nega-
tive regulatory events is influencing viral replication [51]. In 
monocytes, miR-1236 was shown to inhibit HIV-1 infection 
by repressing translation of cellular factor Vpr binding pro-
tein, VprBP/DCAF1 [61]. 
 A significant number of host non-coding RNAs have 
been found in Hepatocellular carcinoma (HCC) caused by 
HCV infection, and are involved in pathogenesis of HCV 
and HCV-induced HCC [62]. 
1.7. Subversion of IFN Responses 
 The role of type I-IFNs in increasing host susceptibility 
could be explained by modulation of components of the im-
mune response involved in controlling the growth of infec-
tive agents, such as induction of T cell apoptosis, resulting in 
greater IL-10 secretion by phagocytic cells, in turn dampen-
ing the innate immune response. A mechanism by which 
viruses survive inside cells is by inactivating the cellular 
antiviral machinery, or inactivating the RNA interference 
response, acting on the dsRNA-activated protein kinase 
(PKR). Infection thus can escape from the immune response 
by deregulation of the interferon signaling and the processes 
forming small RNAs acting in RNA silencing pathways. 
1.8. Virus Deregulation of Stress Granule Function
 It was shown that viral life cycle within cells involves 
hijacking cellular processes and nuclear targeting. This is 
also at the base of redistribution of translation machinery 
during the stress response involving the formation of stress 
granules, processing bodies (P-bodies, PB), and perinuclear 
paraspeckles. During oxidative stress, arsenite, or by phos-
phorylation of eIF2, cells undergo a translation arrest, stall-
ing the RNAs in the form of ternary complexes that include 
eukaryotic initiation factor 2 (eIF2)/GTP/Met-tRNA. These 
stress granules, containing the RNA to be translated, have a 
role in spatial and temporal inhibition of mRNAs, until re-
solving the stress for processing the mRNAs, or degrading it 
in case of non recovery from the stress. Stress granules are 
formed by a nucleation process that involves several princi-
pal factors, such as the RNA decay factor G3BP, which pre-
vents the localisation of ribosome and initiation factors in 
silenced SG foci, the translational suppressor TIA1, TIAR, 
Caprin1, USP10, DDX6 (Rck/p54), DDX3 helicase, poly-A 
binding protein PAPB and Lsm1. Additionally, SGs contain 
enzymes of the RNA silencing pathway, such as Argoanute-
2, trans-acting factors, Hsp90 complexes and RNA binding 
proteins, found at the site of small RNA-mediated repression 
of RNA targets [63]. 
 Different viruses exploit the binding to protein scaffolds 
to avoid SG formation or to assemble their RNA into SGs 
devoid of cellular RNA, thus exploiting the transcriptional 
machinery for their own means [64]. In RNA viruses, the 
knowledge has increased recently, especially focusing on 
HCV infected cells, where SG and P-body components are 
relocalised to the periphery of lipid droplets, and an oscilla-
tion between SG assembly and disassembly is observed upon 
interferon I treatment, depending on the inhibition of PKR 
by the eIF2 phosphatase GADD34 [65]. West Nile Virus 
(WNV) inhibits SG formation by scavenging Reactive Oxy-
gen Species (ROS), and also relocalising the SG scaffolding 
proteins into perinuclear foci where WNV replication occurs 
by exploiting cell translation machinery. HIV-1 blocks SG 
assembly in vitro and ex vivo in patient samples. Gag has an 
important role in inhibition of SG, dependent on the interac-
tion between host factors EIF2 and G3BP1. Influenza A vi-
rus (IAV) proteins can block SG formation: IAV polymerase 
complexes function in the nuclei of infected cells, generating 
mRNAs with a 5’ cap and polyA-tail that are transferred into 
the cytoplasm for translation. Non-structural protein 1 (NS1) 
inactivates PKR, preventing eIF2 phoshorylation; nucleopro-
tein (NP) inhibits SG formation through eIF independent 
mechanisms; host-shutoff protein polymerase-acidic protein-
X (PA-X) is essential to block SG formation. Measles virus 
infection progresses through the synthesis of 5’-copyback 
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defective-interfering RNA (DI-RNAs), that are complemen-
tary in the 5’ and 3’ termini, forming double stranded RNAs, 
efficient in activation of PKR and PKR signaling. Down-
stream to this event, measles protein C is required for alle-
viation of SG translation inhibition, while A-to-C mutation 
events dependent on ADAR modify the virus genome. In 
picornaviruses, such as enteroviruses, proteinases have been 
shown involved in disassembly of SG, while in kobuviruses 
other factors, such as a small leader peptide, are important in 
SG inhibition. 
1.8.1. Vpr/Vpx 
 The viral accessory protein Vpr is a component of the 
PIC. It is reported that Vpr is important on the nuclear im-
port of PIC by interacting with a nuclear pore protein, im-
portin  [29]. Since PIC is larger than a nuclear pore, various 
other nuclear pore complex proteins have also been identi-
fied in PIC nuclear entry, including Nup 98, Nup 124p, Nup 
358 and Nup 153.  
 Vpr belongs to the RAD23-like family of proteins, simi-
larly to Vpx [66]. Vpr is a chaperone that guides target pro-
teins to bind to VprVP/DCAF1, a receptor of the CULLIN 
E3 ubiquitin ligase (Cul4-DDB1, Cul5) [67-69]. Vpx is a 
small virion-associated adaptor protein encoded by viruses 
of the HIV-2/SIVsm lineage of primate lentiviruses, a Vpr 
paralogue, that enables these viruses to infect monocyte-
derived cells. 
 One of the main activities of Vpr/Vpx is the degradation 
of target proteins through binding to VprBP, thus recruiting 
the 26S proteasomal pathway. Several studies showed the 
potentiality of Vpr to interact with many E2 and E3 enzymes 
[70]. Vpr has been shown to affect, either directly or indi-
rectly, the modification of proteins, such as ubiquitinylation, 
phosphorylation and neddylation. In this way, Vpr influences 
and regulates the levels of many proteins [71].  
 Vpr has been found to affect the levels of few miRNAs 
among which is miR-34a, as well as the genes IRBIT, 
SERP1, SIRT1, NEFM, Drp-1, Orai, STIM1, IP3R and 
CREB [72]. It was reported that Vpr inhibits short hairpin 
RNA function as expected upon reduction of endoribonucle-
ase Dicer levels by binding with VprBP to block maturation 
of miRNAs [73].  
 Also it was reported that Vpr can interact with spli-
ceosomal protein SAP145 to mediate cellular pre-mRNA 
splicing inhibition. Although the mechanism is not clarified, 
Vpr is sufficient alone to promote HCV RNA replication 
[74]. Vpr is reported to be a component of the reverse tran-
scription complex (RTC) and co-localizes with the viral nu-
cleic acid and integrase within purified HIV-1 RTCs.  
 Vpr also can regulate several proteins and host factors, 
some of them can affect RNA replication. The most interest-
ing are TERT [67], the type I interferon regulatory factor 3 
(IRF-3) [75], A3G [76], TRIM proteins [77], uracil DNA 
glycosylase 2 (UNG2) [78] and single strand selective mono-
functional uracil-DNA glycosylase 1 (SMUG1). A prema-
ture activation of the SLX4 complex has been shown de-
pendent on Vpr, promoting G2/M arrest and escape from 
innate immune sensing [79]. 
 Zahoor et al. using microarray system found that Vpr 
protein enhanced the mRNA level of interferon (IFN)-
stimulated genes (ISGs), and causes phosphorylation of 
STAT1 at tyrosine 701 in human monocyte-derived macro-
phages (MDMs) infected with a recombinant adenovirus 
expressing Vpr [80]. These findings enhance the current un-
derstanding of HIV-1 replication and pathogenesis in human 
macrophages. Vpr, together with other HIV factors, recruits 
cellular adaptors to facilitate immune evasion [81]. HIV-1 
Vpr differentially regulates the expression levels of chemo-
tactic cytokines such as CXCL1, CXCL5, CXCL7, CXCL9, 
CXCL10, and CXCL11. A report showed that CXCL10 and 
CXCL11 are up-regulated in HIV-1-infected macrophages 
and play a key role in the recruitment and spread of HIV-1 to 
susceptible CD4+ T-cells [82].  
1.9. Intracellular Defences Against HIV 
 Clearly the cell is not a passive participant in virus repli-
cation. In addition to the cellular pathways subverted by the 
virus for its own use there are inhibitory factors within cells 
which act as intracellular defences and whose presence in-
hibits or ‘restricts’ the virus. The first one, identified in ret-
rovirus infected cells, was Fv1 which restricts ecotropic mur-
ine leukemia viruses. Following this finding, other similar 
factors restricting HIV were identified. Because of their po-
tential importance in novel antiviral approaches, they have 
been extensively investigated in recent years. APOBEC3 
family [83], TRIM family [77, 84], Tetherin [85], IRF3 [75], 
SMUG1, UNG2 [86], SAMHD1 [87] and SLX4 [79] were 
well known for being involved in HIV infectivity, indicating 
that the viral proteins can interact and modulate their activ-
ity. 
 As an adaptive response, viruses develop the ability to 
interact and deactivate these defences, a mechanism named 
pathogen mimicry. Among several mechanisms, there are: a) 
the development of proteins and molecules that act interfer-
ing with cellular processes; b) virus miRNA analogs of host 
miRNAs, exploiting the presence of a network of cell effec-
tors and antiapoptotic factors; c) incorporating protein-
protein interaction domains or association modules in their 
genome; d) through increased mutation rates evolving the 
recognition domains of proteins targeted by cellular de-
fences. 
1.9.1. Epigenetics. Resetting of Epigenetic Marks 
 Infective agents and bacteria when entering inside the 
cells activate several mechanisms to avoid immune detection 
[84]. Many viruses entering inside the cells are able to derail 
the cellular machinery, including the epigenetic control. A 
large set of host proteins required for HIV infection have 
been identified through a functional genomic screen [88]. 
RNAi screens have been performed for host factors required 
for HIV replication [30]. 
 HIV-1 integration is generally random but it has more 
easier access into active genes; however, independent of the 
site of integration in human chromosomes, two nucleosomes, 
named nuc-0 and nuc-1, are precisely organized in the 
5LTR. In particular, the histone organized nuc-1 structure 
(located at position 2 to +140 of the LTR) normally serves 
to down modulate basal transcription. 
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 The HIV-1 transcriptional activator Tat has evolved 
mechanisms to resolve the transcription block. Tat is associ-
ated with histone acetyl transferase (HAT) proteins whose 
activities remodel nucleosomes to allow transcriptional ac-
cess. Tat has been shown to bind several different HATs: 
CBP/p300, p/CAF, GCN5, Tip60, and TAFII250. Through 
binding to the HAT proteins, Tat relieves chromatin repres-
sion at the HIV-1 LTR. Recently, Tat has also been found to 
bind a histone chaperone protein, hNAP-1, which acts with 
ATP-dependent chromatin remodeling complexes to facili-
tate transcription.  
 Counteracting the effect of HATs, the histone deacety-
lase proteins (HDAC) remove the acetyl-group from HAT-
acetylated histones to enforce transcriptional silencing. In the 
HIV-1 LTR, it is thought that the LSF protein binds at posi-
tion 10 to +27 of the LTR to recruit the YY1 factor which 
further binds HDAC-1 to silence viral transcription. Tat ex-
pression down regulates HDAC-1 to remove the transcrip-
tion repression. A similar recovery from repressive inhibition 
has been obtained through treatment with HDAC inhibitors 
(HDACIs) such as Trichostatin A (TSA), Valproic Acid 
(VPA), and sodium butyrate. 
1.10. Conclusion 
 In this review we highlighted the importance of cellular 
and viral RNAs in the cell response to RNA viruses, espe-
cially to retroviruses and endogenous L1 remnants of viral 
DNA integration. In addition, we reviewed several pathways 
involving small RNAs and short interfering RNAs deregu-
lated in various states, from active infection to virus-
associated cancers and defective immune signaling. A spe-
cial role has been assigned to the deregulation of interferon 
response and the inhibition of protein complexes in stress 
granules and P-bodies, RNA binding proteins, RISC compo-
nents and the RNA silencing machinery.  
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